| 1 |
Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis |
|
|
| Jonah Larkins-Ford,Talia Greenstein,Nhi Van,Yonatan N. Degefu,Michaela C. Olson,Artem Sokolov,Bree B. Aldridge |
|
| Cell Systems. 2021; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Antituberculosis Drugs (Rifampicin and Isoniazid) Induce Liver Injury by Regulating NLRP3 Inflammasomes |
|
|
| Qiang Su,Wei Kuang,Weiyi Hao,Jing Liang,Liang Wu,Chunmei Tang,Yali Wang,Tao Liu,Young-Su Yi |
|
| Mediators of Inflammation. 2021; 2021: 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis |
|
|
| Shashikant Srivastava,Kayle N. Cirrincione,Devyani Deshpande,Tawanda Gumbo |
|
| Frontiers in Pharmacology. 2021; 11 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Initial In Vivo Evaluation of a Novel Amikacin-Deoxycholate Hydrophobic Salt Delivers New Insights on Amikacin Partition in Blood and Tissues |
|
|
| Styliani Xiroudaki,Federica Ianni,Samuele Sabbatini,Elena Roselletti,Claudia Monari,Roccaldo Sardella,Anna Vecchiarelli,Stefano Giovagnoli |
|
| Pharmaceutics. 2021; 13(1): 85 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Drug-Resistant Tuberculosis 2020: Where We Stand |
|
|
| Angelo Iacobino,Lanfranco Fattorini,Federico Giannoni |
|
| Applied Sciences. 2020; 10(6): 2153 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Addressing Latent Tuberculosis: New Advances in Mimicking the Disease, Discovering Key Targets, and Designing Hit Compounds |
|
|
| André Campaniço,Shrika G. Harjivan,Digby F. Warner,Rui Moreira,Francisca Lopes |
|
| International Journal of Molecular Sciences. 2020; 21(22): 8854 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Differential In Vitro Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved Mycobacterium abscessus |
|
|
| Jin Lee,Nicole Ammerman,Anusha Agarwal,Maram Naji,Si-Yang Li,Eric Nuermberger |
|
| Antimicrobial Agents and Chemotherapy. 2020; 65(2) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
Effects of Cigarette Smoke Condensate on Growth and Biofilm Formation by Mycobacterium tuberculosis |
|
|
| Moloko C. Cholo,Sipho S. M. Rasehlo,Eudri Venter,Chantelle Venter,Ronald Anderson |
|
| BioMed Research International. 2020; 2020: 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 9 |
Molecule Property Analyses of Active Compounds for Mycobacterium Tuberculosis |
|
|
| Vadim Makarov,Elena Salina,Robert C. Reynolds,Phyo Phyo Kyaw Zin,Sean Ekins |
|
| Journal of Medicinal Chemistry. 2020; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 10 |
Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs In Vitro |
|
|
| E. D. Pieterman,M. J. Sarink,C. Sala,S. T. Cole,J. E. M. de Steenwinkel,H. I. Bax |
|
| Antimicrobial Agents and Chemotherapy. 2020; 64(7) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 11 |
Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients |
|
|
| Michael A. Lyons |
|
| Antimicrobial Agents and Chemotherapy. 2019; 63(12) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 12 |
Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence |
|
|
| Saif Khan,Raju K. Mandal,Abdulbaset Mohamed Elasbali,Sajad A. Dar,Arshad Jawed,Mohd Wahid,Harishankar Mahto,Mohtashim Lohani,Bhartendu Nath Mishra,Naseem Akhter,Ali A. Rabaan,Shafiul Haque |
|
| Bioscience Reports. 2019; 39(1) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 13 |
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH |
|
|
| Angelo Iacobino,Federico Giannoni,Manuela Pardini,Giovanni Piccaro,Lanfranco Fattorini |
|
| Antimicrobial Agents and Chemotherapy. 2019; 63(7) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 14 |
Modeling of Mycobacterium tuberculosis dormancy in bacterial cultures |
|
|
| Yana R. Batyrshina,Yakov Sh Schwartz |
|
| Tuberculosis. 2019; 117: 7 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 15 |
Novel MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis and Synergize with Electron Transport Chain Inhibitors |
|
|
| Bryan J. Berube,Dara Russell,Lina Castro,Seoung-ryoung Choi,Prabagaran Narayanasamy,Tanya Parish |
|
| Antimicrobial Agents and Chemotherapy. 2019; 63(6) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 16 |
A rapid, low pH, nutrient stress, assay to determine the bactericidal activity of compounds against non-replicating Mycobacterium tuberculosis |
|
|
| Julie V. Early,Steven Mullen,Tanya Parish,Adelaide Almeida |
|
| PLOS ONE. 2019; 14(10): e0222970 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 17 |
Development and biological evaluation of a new nanotheranostic for tuberculosis |
|
|
| Edward Helal-Neto,Suyene Rocha Pinto,Filipe Leal Portilho,Marcellus Dias da Costa,Jonathas Xavier Pereira,Fiammetta Nigro,Eduardo Ricci-Junior,Andre Luis Peixoto Candéa,Maria das Graças Muller de Oliveira Henri,Ralph Santos-Oliveira |
|
| Drug Delivery and Translational Research. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 18 |
Activity of DNA-targeted C8-linked pyrrolobenzodiazepine–heterocyclic polyamide conjugates against aerobically and hypoxically grown Mycobacterium tuberculosis under acidic and neutral conditions |
|
|
| Angelo Iacobino,Federico Giannoni,Lanfranco Fattorini,Federico Brucoli |
|
| The Journal of Antibiotics. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
